Reuters Examines Questions Surrounding Sanofi’s, WHO’s Responsibilities In Bringing Dengue Vaccine To Market
Reuters: Did Sanofi, WHO ignore warning signals on dengue vaccine?
“…[Sanofi’s dengue vaccine] trial also showed that in the third year after receiving the Dengvaxia inoculation, younger children were more likely to end up in hospital with a severe case of dengue than those who didn’t get the vaccine. … The case raises questions whether Sanofi and the WHO, in their pursuit of a new weapon to fight a deadly disease, should have foreseen the risk. Their decisions on how the vaccine was rolled out could set back efforts to combat dengue by a generation, some disease experts say. Sanofi has rejected suggestions it ignored any risks or took any short-cuts. However, it has acknowledged that clinical tests of the vaccine did not fully investigate whether a previous dengue infection could influence the outcome…” (Steenhuysen/Hirschler, 12/12).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.